Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting

Core Insights - Olema Pharmaceuticals is set to present preclinical data on OP-3136, a selective KAT6 inhibitor, at the AACR Annual Meeting, showcasing its anti-tumor activity in various cancer models [1][2] Group 1: OP-3136 Details - OP-3136 is a novel, orally available small molecule that selectively inhibits lysine acetyltransferase 6 (KAT6), which is an epigenetic target involved in breast and other cancers [3] - Preclinical studies indicate that OP-3136 exhibits significant anti-proliferative activity in ER+ breast cancer models and shows synergistic effects with endocrine therapies such as palazestrant and CDK4/6 inhibitors [3] - The FDA cleared the Investigational New Drug (IND) application for OP-3136 in December 2024, and the Phase 1 clinical trial is currently enrolling patients [3] Group 2: Company Overview - Olema Oncology is a clinical-stage biopharmaceutical company focused on improving treatment standards and outcomes for patients with breast cancer and other related conditions [4] - The company is advancing a pipeline of novel therapies, including its lead product candidate, palazestrant (OP-1250), which is currently in a Phase 3 clinical trial [4] - Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts [4]